Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 80
Filtrar
1.
Eur J Neurol ; 24(2): 391-396, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-28009079

RESUMO

BACKGROUND AND PURPOSE: Ethnicity-related differences in the incidence of acute disseminated encephalomyelitis (ADEM) and other demyelinating diseases including multiple sclerosis and neuromyelitis optica spectrum disorders have been reported. Little is reported on the influence of ethnicity and geographical location in ADEM. METHODS: Medical records of patients who presented with ADEM (ICD-9 323.61 and 323.81) at large referral hospitals in China, Singapore and Japan (years 1992-2015) were retrospectively reviewed and data were collected in a centralized database. Presenting features and outcomes of ADEM were compared between this multi-country Asian cohort and a uniformly collected US cohort using risk differences and risk ratios. Both cohorts were standardized to a 35% pediatric population to facilitate the comparison. RESULTS: There were 83 Asian patients (48 male, 16 pediatric) followed for a median of 2 (25th-75th percentile 1-10) months. Asian patients exhibited a 26% higher prevalence of spinal cord involvement on magnetic resonance imaging [95% confidence interval (CI) 0-52%; P = 0.05; 63% vs. 37%], a 39% lower prevalence of preceding events (95% CI 12-65%; P < 0.01; 33% vs. 72%) and a 23% lower prevalence of corpus callosum involvement (95% CI 7-39%; P < 0.01; 8% vs. 31%). No difference was observed between the two cohorts in the probability of relapse over the first year after disease onset. CONCLUSIONS: It is hypothesized that the high proportion of Asian patients with spinal cord lesions relates to genetic vulnerability or the higher incidence of neuromyelitis optica spectrum disorders in Asia or could be a spurious association. ADEM presentations most probably vary across geographical settings or ethnicities.


Assuntos
Encefalomielite Aguda Disseminada/epidemiologia , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Povo Asiático , Criança , Pré-Escolar , China/epidemiologia , Corpo Caloso/patologia , Bases de Dados Factuais , Encefalomielite Aguda Disseminada/patologia , Feminino , Humanos , Incidência , Japão/epidemiologia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Medição de Risco , Singapura/epidemiologia , Medula Espinal/patologia , Resultado do Tratamento , Estados Unidos/epidemiologia , Adulto Jovem
2.
Eur J Neurol ; 21(7): 1002-10, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24684299

RESUMO

BACKGROUND AND PURPOSE: Muscle atrophy is generally mild in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) compared with the severity and duration of the muscle weakness. Muscle atrophy was evaluated using computed tomography (CT) in patients with CIDP. METHODS: Thirty-one patients with typical CIDP who satisfied the diagnostic criteria for the definite CIDP classification proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society were assessed. The clinicopathological findings in patients with muscle atrophy were also compared with those in patients without atrophy. RESULTS: Computed tomography evidence was found of marked muscle atrophy with findings suggestive of fatty degeneration in 11 of the 31 patients with CIDP. CT-assessed muscle atrophy was in the lower extremities, particularly in the ankle plantarflexor muscles. Muscle weakness, which reflects the presence of muscle atrophy, tended to be more pronounced in the lower extremities than in the upper extremities in patients with muscle atrophy, whereas the upper and lower limbs tended to be equally affected in patients without muscle atrophy. Nerve conduction examinations revealed significantly greater reductions in compound muscle action potential amplitudes in the tibial nerves of patients with muscle atrophy. Sural nerve biopsy findings were similar in both groups. The functional prognoses after immunomodulatory therapies were significantly poorer amongst patients with muscle atrophy. CONCLUSIONS: Muscle atrophy was present in a subgroup of patients with CIDP, including patients with a typical form of the disease. These patients tended to demonstrate predominant motor impairments of the lower extremities and poorer functional prognoses.


Assuntos
Atrofia Muscular/diagnóstico por imagem , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Atrofia Muscular/etiologia , Atrofia Muscular/fisiopatologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/complicações , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/fisiopatologia , Prognóstico , Nervo Sural/patologia
3.
J Neurol ; 259(2): 318-26, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21850388

RESUMO

Our aim was to determine regional brain atrophy in Parkinson's disease (PD) patients with excessive daytime sleepiness (EDS) using voxel-based morphometry (VBM). From 71 consecutive probable PD patients, nine non-demented and non-hallucinating patients with an Epworth Sleepiness Scale (ESS) ≥ 10 and 13 PD patients with an ESS ≤ 3 were selected as having EDS and as not having EDS, respectively. We also enrolled 22 healthy age- and sex-matched controls. Regional brain atrophy was assessed using VBM with 3-T magnetic resonance imaging. There was no difference in the dosage of dopaminergic drugs between PD patients with EDS and PD patients without EDS. PD patients with EDS showed marked atrophy in the gray matter of the frontal lobe, temporal lobe, occipital lobe, limbic lobe including the nucleus basalis of Meynert compared to controls (false discovery rate corrected p < 0.05). In contrast, PD patients without EDS did not show any significant difference in gray matter atrophy compared to controls (false discovery rate corrected p < 0.05). PD patients with EDS showed significant atrophy of the frontal lobe, temporal lobe, occipital lobe, limbic lobe including the nucleus basalis of Meynert compared to PD patients without EDS (uncorrected p < 0.001). PD patients with EDS, even without dementia and hallucination, showed significant gray matter atrophy compared to PD patients without EDS and controls.


Assuntos
Encéfalo/patologia , Distúrbios do Sono por Sonolência Excessiva/etiologia , Distúrbios do Sono por Sonolência Excessiva/patologia , Doença de Parkinson/complicações , Doença de Parkinson/patologia , Idoso , Atrofia , Feminino , Humanos , Interpretação de Imagem Assistida por Computador , Imageamento por Ressonância Magnética , Masculino
4.
J Neurol Sci ; 309(1-2): 148-50, 2011 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-21839479

RESUMO

We report a 47-year-old woman who manifested ocular motility disorder, bilateral pyramidal signs, and severe parkinsonism after a ventriculo-peritoneal shunt for non communicating hydrocephalus secondary to idiopathic aqueduct stenosis. The ocular motility disorder consisted of severe vertical gaze palsy and convergence retraction nystagmus. Parkinsonism included not only bradykinesia but also resting tremor and cogwheel rigidity. On the other hand, striatal uptake did not decrease in (18)F-dihydroxyphenylalanine positron emission tomography, and anti-Parkinsonian drugs were not effective. 99mTc-ethyl cysteinate dimer bicisate single-photon emission computed tomography and F-18 fluorodeoxyglucose positron emission tomography revealed wide-ranged frontal cerebral cortical dysfunction due to midbrain dysfunction. Moreover, endoscopic third ventriculotomy markedly improved the clinical symptoms as well as the frontal cerebral cortical flow. A neural network formation known as the 'cortico-basal ganglia loop,' which intimately connects the frontal lobe with the basal ganglia, is possibly associated with the Parkinsonism observed in our patient.


Assuntos
Hidrocefalia/cirurgia , Transtornos Parkinsonianos/diagnóstico , Derivação Ventriculoperitoneal/efeitos adversos , Ventriculostomia , Endoscopia/métodos , Feminino , Humanos , Hidrocefalia/complicações , Hidrocefalia/diagnóstico , Hidrocefalia/etiologia , Pessoa de Meia-Idade , Transtornos Parkinsonianos/etiologia , Ventriculostomia/métodos
5.
Neurology ; 76(16): 1372-6, 2011 Apr 19.
Artigo em Inglês | MEDLINE | ID: mdl-21411744

RESUMO

BACKGROUND: Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in neuronal and somatic cells. Because of the variety of clinical manifestations, antemortem diagnosis of NIID is difficult. METHODS: Seven skin biopsy samples from patients with familial NIID were evaluated histochemically, and the results were compared with those of skin samples from normal control subjects and from patients with other neurologic diseases. We also examined skin biopsy samples from patients with NIID by electron microscopy. RESULTS: In NIID skin biopsy samples, intranuclear inclusions were observed in adipocytes, fibroblasts, and sweat gland cells. These inclusions were stained with both anti-ubiquitin and anti-SUMO1 antibodies. Electron microscopy revealed that the features of the intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells were identical to those of neuronal cells. Approximately 10% of adipocytes showed intranuclear inclusions. No intranuclear inclusions were identified in the skin samples from normal control subjects and patients with other neurologic diseases. CONCLUSIONS: Skin biopsy is an effective and less invasive antemortem diagnostic tool for NIID.


Assuntos
Diagnóstico , Corpos de Inclusão Intranuclear/patologia , Pele/patologia , Pele/ultraestrutura , Biópsia/métodos , Humanos , Indóis , Corpos de Inclusão Intranuclear/metabolismo , Corpos de Inclusão Intranuclear/ultraestrutura , Microscopia Eletrônica de Transmissão/métodos , Doenças Neurodegenerativas/diagnóstico , Neuroglia/metabolismo , Neuroglia/patologia , Neuroglia/ultraestrutura , Neurônios/metabolismo , Neurônios/patologia , Neurônios/ultraestrutura , Proteína SUMO-1/metabolismo , Ubiquitina/metabolismo
7.
Curr Mol Med ; 11(1): 48-56, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21189118

RESUMO

Transforming growth factor ß (TGF-ß), a pleiotropic cytokine, regulates a diverse range of cellular responses, such as proliferation, differentiation, migration, and apoptosis. The TGF-ß1, -ß2, and -ß3 isoforms are expressed by neurons and glial cells, and their receptors are expressed throughout the central nervous system. Several lines of evidence demonstrate that TGF-ß signaling protects neurons from glutamate-mediated excitotoxicity, a putative mechanism underlying the pathogenesis of various neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). Recent studies indicate that the TGF-ß-Smad2/3 pathway restores motor function in a mouse model of ALS, and that disruption of TGF-ß signaling due to the transcriptional dysregulation of its receptor is associated with polyglutamine-induced motor neuron damage in spinal and bulbar muscular atrophy. Moreover, the TGF-ß-Smad2/3 pathway regulates the function of glial cells, although the implication of this regulation in neurodegeneration remains elusive. Conversely, myostatin, a member of the TGF-ß superfamily, has gained attention as a potential therapeutic target for neuromuscular disorders because genetic deletion of this factor results in increased muscle volume. Signal transduction by BMP, a member of the TGF-ß super family, regulates the function and growth of the neuromuscular junction, while the disruption of this signaling has been reported in animal models of hereditary spastic paraplegia. These findings support the hypothesis that the disruption of TGF-ß signaling is an important molecular event in the pathogenesis of motor neuron diseases, and that the modification of this signaling pathway represents a new therapeutic strategy against these devastating disorders.


Assuntos
Doença dos Neurônios Motores/metabolismo , Paraplegia Espástica Hereditária/metabolismo , Fator de Crescimento Transformador beta/fisiologia , Animais , Humanos , Doença dos Neurônios Motores/patologia , Doença dos Neurônios Motores/fisiopatologia , Neurônios Motores/fisiologia , Músculo Esquelético/metabolismo , Junção Neuromuscular/fisiologia , Receptores de Fatores de Crescimento Transformadores beta/metabolismo , Transdução de Sinais , Paraplegia Espástica Hereditária/fisiopatologia
9.
Neurology ; 73(17): 1348-52, 2009 Oct 27.
Artigo em Inglês | MEDLINE | ID: mdl-19776380

RESUMO

OBJECTIVE: Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by immune-mediated peripheral demyelination. Although corticosteroid, IV immunoglobulin (IVIg) and plasma exchange have been established as the most effective therapeutics, subpopulations of patients show little or no response to either of these therapies. In this study, we examined whether particular genetic factors influence the therapeutic responsiveness of patients with CIDP. METHODS: One hundred Japanese patients categorized as responders or nonresponders to IVIg therapy participated in our study. We performed an association analysis with single nucleotide polymorphisms (SNPs) and haplotype studies between the IVIg responders and nonresponders. RESULTS: Two separate SNPs, corresponding to TAG-1 (transient axonal glycoprotein 1) and CLEC10A (C-type lectin domain family 10, member A), showed strong significant differences between responders and nonresponders. Haplotype analysis of a series of expanded SNPs, from TAG-1 or CLEC10A, showed that only TAG-1 included a significant haplotype within 1 linkage disequilibrium block, which accommodates IVIg responsiveness. Diplotype analysis of TAG-1 also supported this observation. CONCLUSIONS: Transient axonal glycoprotein 1 is a crucial molecule involved in IV immunoglobulin responsiveness in Japanese patients with chronic inflammatory demyelinating polyneuropathy.


Assuntos
Moléculas de Adesão Celular Neuronais/genética , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Polimorfismo de Nucleotídeo Único , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/tratamento farmacológico , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Contactina 2 , Feminino , Haplótipos , Humanos , Japão/epidemiologia , Lectinas Tipo C/genética , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/epidemiologia , Análise de Sequência de DNA , Índice de Gravidade de Doença , Resultado do Tratamento
10.
Neurology ; 72(7): 621-6, 2009 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-19221295

RESUMO

OBJECTIVE: To elucidate the usefulness of plasma B-type natriuretic peptide (BNP) values for evaluating adverse effects of pergolide or cabergoline on cardiovalvulopathy in patients with Parkinson disease. METHODS: Twenty-five patients treated with pergolide or cabergoline (ergot group) and 25 patients never treated with ergot derivatives (non-ergot group) were enrolled. Plasma BNP values and detailed echocardiography were evaluated. Thirty age- and gender-matched controls were similarly evaluated. RESULTS: Patients with regurgitation more than grade 3 were more frequent in the ergot group than in the non-ergot group as well as control groups (24%, 0%, 3%, p = 0.001). Both composite regurgitation scores and plasma BNP values were significantly higher in the ergot group than in controls. In the ergot group, the cumulative dose correlated to both tenting area (r = 0.57, p = 0.004) and tenting distance (r = 0.62, p = 0.001). Furthermore, plasma BNP values were higher in patients with severe or multiple regurgitation groups (p < 0.001), and were correlated with composite regurgitation score (r = 0.70, p < 0.001). Multiple regression analyses revealed that BNP values were independently correlated with both composite regurgitation and left ventricular ejection fraction. CONCLUSION: The combination of comprehensive echocardiography and plasma B-type natriuretic peptide levels elucidates the presence of cardiac damage in patients with Parkinson disease using ergot derivative dopamine agonists.


Assuntos
Agonistas de Dopamina/uso terapêutico , Insuficiência da Valva Mitral/sangue , Peptídeo Natriurético Encefálico/sangue , Doença de Parkinson/sangue , Insuficiência da Valva Tricúspide/sangue , Idoso , Biomarcadores/sangue , Estudos de Coortes , Agonistas de Dopamina/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência da Valva Mitral/induzido quimicamente , Insuficiência da Valva Mitral/complicações , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológico , Insuficiência da Valva Tricúspide/induzido quimicamente , Insuficiência da Valva Tricúspide/complicações
11.
J Neurol Neurosurg Psychiatry ; 79(9): 1040-3, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18223015

RESUMO

OBJECTIVE AND METHODS: To characterise the epidemiological features of chronic inflammatory demyelinating polyneuropathy (CIDP) in the Japanese population, this study performed a nationwide assessment of the prevalence and incidence rates in Japan. RESULTS: The prevalence rate per 100 000 was 1.61 in the total population; 2.01 in males and 1.23 in females. The age dependent prevalence rates were 0.23 in juveniles (<15 years old), 1.50 in young adults (15-55 years) and 2.31 in elderly adults (>55 years). The sex and age dependent prevalence rates were 0.22 in males and 0.24 in females in juveniles, 1.81 in males and 1.19 in females in young adults, and 3.12 in males and 1.64 in females in elderly adults. The annual incidence rate per 100 000 was 0.48 in the total population, 0.58 in males and 0.38 in females. The age dependent incidence rate was 0.06 in juveniles, 0.40 in young adults and 0.73 in elderly adults. The sex and age dependent incidence rate was 0.05 in males and 0.08 in females in juveniles, 0.50 in males and 0.30 in females in young adults, and 0.93 in males and 0.58 in females in elderly adults. Both the prevalence and incidence rates were very similar throughout the eight geographical areas studied, from the northern to the southern parts of Japan. CONCLUSIONS: The prevalence and incidence rates were similar to those reported in the Caucasian population. The pathogenic background is suggested to be common throughout the different races and geographic areas, while gender and age effects should be taken into account in the pathogenesis of CIDP.


Assuntos
Síndrome de Guillain-Barré/epidemiologia , Síndrome de Guillain-Barré/patologia , Adolescente , Adulto , Criança , Pré-Escolar , Doença Crônica , Feminino , Humanos , Incidência , Lactente , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Inquéritos e Questionários
12.
J Neurol Neurosurg Psychiatry ; 79(5): 496-9, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-17682009

RESUMO

OBJECTIVE: The aim of this study was to evaluate cognitive impairment in patients with spinocerebellar ataxia type 6 (SCA6) and to verify the role of cerebellar involvement in intellectual abilities. METHODS: Cognitive function was examined in 18 patients with genetically confirmed SCA6 and in 21 age and education matched controls using a test battery for attention, verbal and visuospatial memory, as well as executive function. RESULTS: Verbal fluency and immediate visual memory task were markedly impaired in SCA6 compared with the control group (p = 0.007, 0.004 and 0.014, respectively). The results of the Rule Shift Cards Test was reduced in patients with SCA6, but the reduction was not significant. These cognitive dysfunctions did not correlated with CAG repeat length, age at onset, ataxic motor dysfunctional scale or depression. CONCLUSIONS: Our results demonstrate that specific cognitive deficits occur in patients with SCA6, independent of ataxic motor dysfunction. These deficits may reflect disruption of cortico-cerebellar circuits.


Assuntos
Transtornos Cognitivos/diagnóstico , Testes Neuropsicológicos , Ataxias Espinocerebelares/diagnóstico , Adulto , Idoso , Estudos de Casos e Controles , Córtex Cerebelar/fisiopatologia , Córtex Cerebral/fisiopatologia , Transtornos Cognitivos/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Rede Nervosa/fisiopatologia , Distúrbios da Fala/diagnóstico , Distúrbios da Fala/fisiopatologia , Ataxias Espinocerebelares/fisiopatologia , Estatística como Assunto
13.
Neurology ; 69(6): 564-72, 2007 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-17679675

RESUMO

OBJECTIVE: To characterize the clinicopathologic features of ataxic and painful forms of paraneoplastic neuropathy. METHODS: Clinical, electrophysiologic, and histopathologic findings were assessed in 17 patients with paraneoplastic neuropathy. RESULTS: Clinical features can be categorized into two groups: one group (13 patients) with predominantly deep sensory disturbance and a second group (4 patients) with predominantly superficial sensory disturbance. The former group showed severe sensory ataxia and predominantly large myelinated fiber loss in the sural nerve. The latter group showed marked pain, in particular, severe mechanical hyperalgesia, and predominantly small myelinated and unmyelinated fiber loss. Nerve conduction assessment indicated an axonal neuropathy pattern in both groups, while sensory action potentials were more markedly diminished in the sensory ataxic form. Anti-Hu antibodies were detected in half of the patients in both groups. Treatment for cancer was effective to improve or stabilize neuropathic symptoms in some cases from both groups. Immunotherapy was effective only for a short time. CONCLUSIONS: Paraneoplastic neuropathy can be characterized into two groups by the presence of sensory ataxia or severe spontaneous pain and severe mechanical hyperalgesia. Preferential small myelinated and unmyelinated fiber loss correlated to the cases of severe pain.


Assuntos
Marcha Atáxica/etiologia , Neuralgia/etiologia , Degeneração Paraneoplásica Cerebelar/etiologia , Polineuropatia Paraneoplásica/classificação , Potenciais de Ação , Idoso , Anticorpos Antineoplásicos/imunologia , Antineoplásicos/uso terapêutico , Autoanticorpos/imunologia , Autoantígenos/imunologia , Biópsia , Feminino , Humanos , Hipestesia/etiologia , Hipestesia/patologia , Neoplasias Pulmonares/complicações , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/imunologia , Neoplasias/complicações , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico , Degeneração Neural/etiologia , Degeneração Neural/patologia , Fibras Nervosas Mielinizadas/patologia , Fibras Nervosas Amielínicas/patologia , Proteínas do Tecido Nervoso/imunologia , Condução Nervosa , Degeneração Paraneoplásica Cerebelar/imunologia , Degeneração Paraneoplásica Cerebelar/fisiopatologia , Polineuropatia Paraneoplásica/complicações , Polineuropatia Paraneoplásica/imunologia , Polineuropatia Paraneoplásica/fisiopatologia , Reflexo Anormal , Transtornos de Sensação/etiologia , Transtornos de Sensação/patologia , Nervo Sural/patologia , Fatores de Tempo
14.
J Neurol Neurosurg Psychiatry ; 78(8): 899-901, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17635982

RESUMO

A 57-year-old man with type 2 diabetes mellitus for 10 years showed progressive loss of muscle strength in both legs, pain and muscle atrophy in the femoral region and significant weight loss. On admission, he could not stand alone and used a wheelchair. He also complained of severe pain in the lower extremities. He was diagnosed with proximal diabetic neuropathy (PDN) by characteristic clinical and electrophysiological features. Intravenous immunoglobulin therapy (IVIg 0.4 g/kg x 5 days) markedly reduced the severe pain and muscle weakness in the legs. Eventually, pain assessed by the Visual Analogue Scale was relieved by 80% and muscle strength was also well recovered, thereby enabling the patient to walk with a cane. The present case suggests that IVIg therapy may be effective for the relief of pain in PDN.


Assuntos
Nefropatias Diabéticas/tratamento farmacológico , Imunoglobulinas Intravenosas , Debilidade Muscular/tratamento farmacológico , Dor/tratamento farmacológico , Diabetes Mellitus Tipo 2/complicações , Nefropatias Diabéticas/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Dor/etiologia , Resultado do Tratamento
15.
Neuropathol Appl Neurobiol ; 33(2): 135-51, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17359355

RESUMO

Spinal and bulbar muscular atrophy (SBMA) or Kennedy's disease is a motor neurone disease characterized by muscle atrophy, weakness, contraction fasciculations and bulbar involvement. SBMA mainly affects males, while females are usually asymptomatic. SBMA is caused by expansion of a polyglutamine (polyQ)-encoding CAG trinucleotide repeat in the androgen receptor (AR) gene. AR belongs to the heat shock protein 90 (Hsp90) client protein family. The histopathologic hallmarks of SBMA are diffuse nuclear accumulation and nuclear inclusions of the mutant AR with expanded polyQ in residual motor neurones in the brainstem and spinal cord as well as in some other visceral organs. There is increasing evidence that the ligand of AR and molecular chaperones play a crucial role in the pathogenesis of SBMA. The success of androgen deprivation therapy in SBMA mouse models has been translated into clinical trials. In addition, elucidation of its pathophysiology using animal models has led to the development of disease-modifying drugs, that is, Hsp90 inhibitor and Hsp inducer, which inhibit the pathogenic process of neuronal degeneration. SBMA is a slowly progressive disease by nature. The degree of nuclear accumulation of mutant AR in scrotal skin epithelial cells was correlated with that in spinal motor neurones in autopsy specimens; therefore, the results of scrotal skin biopsy may be used to assess the efficacy of therapeutic trials. Clinical and pathological parameters that reflect the pathogenic process of SBMA should be extensively investigated.


Assuntos
Antagonistas de Receptores de Andrógenos , Benzoquinonas/uso terapêutico , Proteínas de Choque Térmico HSP90/antagonistas & inibidores , Lactamas Macrocíclicas/uso terapêutico , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/genética , Animais , Hormônio Liberador de Gonadotropina/análogos & derivados , Proteínas de Choque Térmico HSP90/genética , Humanos , Atrofia Muscular Espinal/patologia , Receptores Androgênicos/genética
16.
J Neurol Sci ; 241(1-2): 31-7, 2006 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-16380134

RESUMO

OBJECTIVE: To compare clinicopathologic findings in nonsystemic vasculitic neuropathy (NSVN) and microscopic polyangiitis-associated neuropathy (MPAN). METHODS: Patients clinicopathologically confirmed to have NSVN (n=23) or MPAN (n=40) were compared with respect to clinical, electrophysiologic, and histopathologic features. RESULTS: Clinical features of neuropathy such as initial symptoms, progression, and distribution of sensory and motor deficits were similar in both groups, while functional compromise was greater in MPAN than NSVN. Abnormalities of laboratory data including those reflecting severity and extent of inflammation such as C-reactive protein were more conspicuous in MPAN than NSVN. Perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) were positive in two-thirds of patients with MPAN but negative in all NSVN. Electrophysiologic and histopathologic findings indicated axonal neuropathy in both groups, whereas the reduction of compound muscle action potentials in the tibial nerve and sensory nerve action potentials in the median nerve was significantly more profound in MPAN than NSVN. As for the epineurial perivascular infiltration, frequencies of cell-specific markers for T lymphocytes, macrophages, and B lymphocytes among cells infiltrating the vasculitic lesions were essentially similar between groups. CONCLUSIONS: Clinicopathologic profiles and vascular pathology were similar between NSVN and MPAN but the age at onset, severity, and presence of p-ANCA were clearly different. Further study is needed to clarify the pathogenesis of NSVN and its place in the vasculitic spectrum of diseases.


Assuntos
Doenças do Sistema Nervoso Periférico/metabolismo , Doenças do Sistema Nervoso Periférico/fisiopatologia , Polineuropatias/metabolismo , Polineuropatias/fisiopatologia , Vasculite/metabolismo , Vasculite/fisiopatologia , Potenciais de Ação/fisiologia , Idade de Início , Idoso , Anticorpos Anticitoplasma de Neutrófilos/metabolismo , Diagnóstico Diferencial , Feminino , Glomerulonefrite/metabolismo , Glomerulonefrite/patologia , Glomerulonefrite/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Condução Nervosa/fisiologia , Doenças do Sistema Nervoso Periférico/patologia , Polineuropatias/patologia , Estatísticas não Paramétricas , Nervo Sural/fisiopatologia , Vasculite/patologia
17.
Neurology ; 64(8): 1471-5, 2005 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-15851750

RESUMO

To identify clinical and electrophysiologic features related to IV immunoglobulin (IVIg) responsiveness in chronic inflammatory demyelinating polyneuropathy (CIDP), the authors conducted a multicenter study on 312 patients with CIDP (199 responders and 113 nonresponders). Muscle atrophy and decreased compound muscle action potential were pronounced in nonresponders of IVIg. Male gender, longer disease duration, and slow progression of symptoms were also associated with IVIg unresponsiveness. Features suggesting axonal dysfunction in peripheral nerves indicated IVIg unresponsiveness in CIDP.


Assuntos
Imunoglobulinas Intravenosas/farmacologia , Imunoglobulinas Intravenosas/uso terapêutico , Nervos Periféricos/efeitos dos fármacos , Nervos Periféricos/fisiopatologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/tratamento farmacológico , Adulto , Idade de Início , Idoso , Axônios/efeitos dos fármacos , Axônios/imunologia , Axônios/patologia , Progressão da Doença , Resistência a Medicamentos/imunologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neurônios Motores/efeitos dos fármacos , Neurônios Motores/imunologia , Neurônios Motores/patologia , Atrofia Muscular/tratamento farmacológico , Atrofia Muscular/imunologia , Atrofia Muscular/fisiopatologia , Condução Nervosa/efeitos dos fármacos , Condução Nervosa/imunologia , Neurônios Aferentes/efeitos dos fármacos , Neurônios Aferentes/imunologia , Neurônios Aferentes/patologia , Nervos Periféricos/imunologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/imunologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/fisiopatologia , Fatores Sexuais , Resultado do Tratamento
18.
J Neurol Neurosurg Psychiatry ; 75(1): 103-9, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14707317

RESUMO

OBJECTIVE: We performed (1)H-MR spectroscopy ((1)H-MRS) on multiple brain regions to determine the metabolite pattern and diagnostic utility of (1)H-MRS in multiple system atrophy (MSA). METHODS: Examining single voxels at 3.0 T, we studied metabolic findings of the putamen, pontine base, and cerebral white matter in 24 MSA patients (predominant cerebellar ataxia (MSA-C), n = 13), parkinsonism (MSA-P), n = 11), in 11 age and duration matched Parkinson's disease patients (PD) and in 18 age matched control subjects. RESULTS: The N-acetylaspartate to creatine ratio (NAA/Cr) in MSA patients showed a significant reduction in the pontine base (p<0.0001) and putamen (p = 0.02) compared with controls. NAA/Cr in cerebral white matter also tended to decline in long standing cases. NAA/Cr reduction in the pontine base was prominent in both MSA-P (p<0.0001) and MSA-C (p<0.0001), and putaminal NAA/Cr reduction was significant in MSA-P (p = 0.009). It was also significant in patients who were in an early phase of their disease, and in those who showed no ataxic symptoms or parkinsonism, or did not show any MRI abnormality of the "hot cross bun" sign or hyperintense putaminal rims. NAA/Cr in MSA-P patients was significantly reduced in the pontine base (p = 0.001) and putamen (p = 0.002) compared with PD patients. The combined (1)H-MRS in the putamen and pontine base served to distinguish patients with MSA-P from PD more clearly. CONCLUSIONS: (1)H-MRS showed widespread neuronal and axonal involvement in MSA. The NAA/Cr reduction in the pontine base proved highly informative in the early diagnosis of MSA prior to MRI changes and even before any clinical manifestation of symptoms.


Assuntos
Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Creatina/metabolismo , Espectroscopia de Ressonância Magnética , Atrofia de Múltiplos Sistemas/diagnóstico , Tronco Encefálico/patologia , Tronco Encefálico/fisiologia , Estudos de Casos e Controles , Córtex Cerebral/patologia , Córtex Cerebral/fisiologia , Diagnóstico Diferencial , Feminino , Humanos , Hidrogênio , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/fisiopatologia , Putamen/patologia , Putamen/fisiologia , Valores de Referência
19.
Cytogenet Genome Res ; 100(1-4): 243-51, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14526186

RESUMO

Spinal and bulbar muscular atrophy (SBMA) is a late-onset motor neuron disease characterized by proximal muscle atrophy, weakness, contraction fasciculations, and bulbar involvement. Only males develop symptoms, while female carriers usually are asymptomatic. A specific treatment for SBMA has not been established. The molecular basis of SBMA is the expansion of a trinucleotide CAG repeat, which encodes the polyglutamine (polyQ) tract, in the first exon of the androgen receptor (AR) gene. The pathologic hallmark is nuclear inclusions (NIs) containing the mutant and truncated AR with expanded polyQ in the residual motor neurons in the brainstem and spinal cord as well as in some other visceral organs. Several transgenic (Tg) mouse models have been created for studying the pathogenesis of SBMA. The Tg mouse model carrying pure 239 CAGs under human AR promoter and another model carrying truncated AR with expanded CAGs show motor impairment and nuclear NIs in spinal motor neurons. Interestingly, Tg mice carrying full-length human AR with expanded polyQ demonstrate progressive motor impairment and neurogenic pathology as well as sexual difference of phenotypes. These models recapitulate the phenotypic expression observed in SBMA. The ligand-dependent nuclear localization of the mutant AR is found to be involved in the disease mechanism, and hormonal therapy is suggested to be a therapeutic approach applicable to SBMA.


Assuntos
Modelos Animais de Doenças , Atrofia Muscular Espinal/genética , Receptores Androgênicos/genética , Expansão das Repetições de Trinucleotídeos/genética , Animais , Feminino , Humanos , Masculino , Camundongos , Camundongos Transgênicos , Atrofia Muscular Espinal/patologia , Fenótipo , Fatores Sexuais
20.
J Mol Evol ; 52(6): 502-9, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11443353

RESUMO

A simplified experimental evolution encompassing the essence of natural one was designed in an attempt to understand the involved mechanism. In our system, molecular evolution was observed through three serial cycles of consecutive random mutagenesis of the glutamine synthetase gene and chemostat culture of the transformed Escherichia coli cells containing the mutated genes. Selection pressure was imposed solely on the glutamine synthetase gene when varieties of mutant genes compete in an unstructured environment of the chemostat. The molecular phylogeny and population dynamics were deduced from the nucleotide sequences of the genes isolated from each of the chemostat runs. An initial mutant population in each cycle, comprised of diversified closely-related genes, ended up with several varieties of mutants in a state of coexistence. Competition between two mutant genes in the final population of the first cycle ascertained that the observed coexisting state is not an incidental event and that cellular interaction via environmental nutrients is a possible mechanism of coexistence. In addition, the mutant gene once extinct in the previous passage was found to have the capacity to reinvade and constitute the gene pool of the later cycle of molecular evolution. These results, including the kinetic characteristics of the purified wild-type and mutant glutamine synthetases in the phylogenetic tree, revealed that the enzyme activity had diverged, rather than optimized, to a fittest value during the course of evolution. Here, we proposed that the plasticity of gene fitness in consequence of cellular interaction via the environment is an essential mechanism governing molecular evolution.


Assuntos
Evolução Molecular , Escherichia coli/enzimologia , Escherichia coli/genética , Glutamato-Amônia Ligase/genética , Glutamina/metabolismo , Cinética , Mutagênese , Mutação , Filogenia , Plasmídeos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA